Both CRISPR Therapeutics AG (NASDAQ:CRSP) and Zealand Pharma A/S (NASDAQ:ZEAL) are each other’s competitor in the Biotechnology industry. Thus the compare of their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CRISPR Therapeutics AG | 54 | 0.00 | 34.37M | -3.74 | 0.00 |
| Zealand Pharma A/S | 30 | 0.00 | 26.77M | 3.00 | 7.54 |
Table 1 highlights CRISPR Therapeutics AG and Zealand Pharma A/S’s gross revenue, earnings per share (EPS) and valuation.
Profitability
Table 2 has CRISPR Therapeutics AG and Zealand Pharma A/S’s return on equity, return on assets and net margins.
| Net Margins | Return on Equity | Return on Assets | |
| CRISPR Therapeutics AG | 63,507,021.43% | -50.9% | -39.8% |
| Zealand Pharma A/S | 87,914,614.12% | 0% | 0% |
Analyst Recommendations
CRISPR Therapeutics AG and Zealand Pharma A/S Recommendations and Ratings are available on the next table.
| Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
| CRISPR Therapeutics AG | 0 | 0 | 4 | 3.00 |
| Zealand Pharma A/S | 0 | 0 | 2 | 3.00 |
CRISPR Therapeutics AG has a consensus price target of $66.5, and a -8.11% downside potential. On the other hand, Zealand Pharma A/S’s potential upside is 11.04% and its consensus price target is $36.5. The results provided earlier shows that Zealand Pharma A/S appears more favorable than CRISPR Therapeutics AG, based on analyst opinion.
Institutional & Insider Ownership
CRISPR Therapeutics AG and Zealand Pharma A/S has shares held by institutional investors as follows: 50% and 9%. Insiders held roughly 2% of CRISPR Therapeutics AG’s shares.
Performance
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| CRISPR Therapeutics AG | 3.15% | 6.25% | 30.58% | 57.23% | 7.51% | 77.42% |
| Zealand Pharma A/S | -1.05% | 3.57% | 8.69% | 53.95% | 52.19% | 94.92% |
For the past year CRISPR Therapeutics AG’s stock price has smaller growth than Zealand Pharma A/S.
Summary
Zealand Pharma A/S beats on 8 of the 11 factors CRISPR Therapeutics AG.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
